pacibekitug

News

Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.